Equis ISSN 2398-2977

Dinoprost tromethamine

Contributor(s): Simon Staempfli, Vetstream Ltd, Madeleine Campbell

Introduction

Name

  • Dinoprost tromethamine.

Class of drug

  • Prostaglandin.
  • Prostaglandin F2α (PGF2α).

Description

Chemical name

  • 2-amino-2-(hydroxymethyl)propane-1,3-diol.

Molecular formula

  • C20H34O5.C4H11NO3; C24H45NO8.

Molecular weight

  • 475.62.

Physical properties

  • Supplied as a clear, aqueous solution for injection.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Licensed uses

  • Termination of normal luteal phase (including induction of estrus in mares with persistent luteal function/to control timing of estrus).
  • Termination of pregnancy/induction of abortion in the earlier stages of pregnancy (up to day 35) during which the maintenance of pregnancy is dependent upon the corpus luteum as the sole source of progesterone.
Use of Prostaglandin F2α (PGF2α) can induce termination of pregnancy/abortion later in pregnancy, but this is probably due to an effect on uterine contractions rather than through causing luteolysis).

Unlicensed uses

Do no use cloprostenol for this purpose after ovulation following breeding as may cause luteolysis.
  • Induction of maternal behavior in foster mares.
These are off license uses which should only be undertaken under prescription cascade, and for which (written) informed consent should be obtained from animal owners prior to use.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Barker K J, Mateu Sánchez S, Serrano Y R, Lacey F M & Crabtree J R (2019) Prostaglandin F2 alpha-induced maternal behaviour for fostering orphan foals and for mares demonstrating foal rejection. Equine Vet J 61, S53.
  • Holland B & Pinto C R F (2008) Luteal function and ovulation in mares treated with PGF2a during early and mid-diestrus. Reprod Domest Anim 43 (Suppl 3), 111 Wiley.
  • Barker C, Echeverria K & Davis M (2006) Effects of different doses of PGF2 on luteal function and on the subsequent estrous cycle. Anim Reprod Sci 94, 207–209.
  • Bergfelt D R, Pierson R A & Ginther O J (2006) Regression and resurgence of the CL following PGF2alpha treatment 3 days after ovulation in mares. Theriogenology 65 (8), 1605-1619 PubMed.
  • Klem M E Jr, Kreider J L, Harms P G, Potter G D, Kraemer D C & Godke R A (1982) Induction of parturition in the mare with prostaglandin F2 alpha. Prostaglandins 24 (1), 89-96 PubMed.

Other sources of information

  • Staempfli S A (2011) Pharmacologic Manipulation of Reproduction: Prostaglandins. In: Equine Reproduction. 2nd edn. Eds: McKinnon A O, Squires E L, Vaala W E & Varner D D. Wiley-Blackwell. pp 1797-1804.
  • The NOAH Compendium of datasheets of licensed veterinary medicines. Available at: https://www.noahcompendium.co.uk.
  • Veterinary Medicines Directorate. Adverse Reaction Reporting. Available at: https://www.vmd.defra.gov.uk.
  • Veterinary Medicines Directorate. Questions and Answers on FDA's Adverse Event Reporting System (FAERS). Available at: https://www.fda.gov/drugs.

ADDED